Advertisement

A Prospective Pilot Study Evaluating The Hrqol Impact Of A Novel Air Purification Technology For Pediatric Asthma Patients

      Objectives

      To evaluate the impact of the HEPAiRx® technology on the quality of life (QoL) and asthma related outcomes for a pediatric asthma population.

      Methods

      The HEPAiRx® is a window mounted patented room-air purifier with HEPA filtration for particulate removal and fresh outside air exchange for VOC removal that effectively reduces indoor air pollutants that have been associated with asthma. It also has built-in heating and air conditioning so the room can be isolated from surrounding spaces and contaminants. The intended sample size for this study was 25; however three subjects were enrolled due to recruitment difficulties. The 16-week prospective portion of the study consisted of 4 home visits. Health care resources, a daily diary, pulmonary function tests (PFTs), Forced Vital Capacity (FVC), Forced Expiratory Volume (FEV1) and QoL outcomes were captured. Health care resources were captured retrospectively for the same calendar period in the previous year. The validated Pediatric Asthma Quality of Life Questionnaire (PAQLQ) and Pediatric Asthma Caregiver Quality of Life Questionnaire (PACQLQ) were administered.

      Results

      The PFTs indicated improvement over the prospective period. FVC mean value improved by 18.6% from baseline to week 16; FEV1 mean value improved by 22.0%. The PAQLQ instrument indicated an improvement in the subjects’ asthma related QoL; the symptom domain score increased by 46.8% from baseline to week 16. The overall score increased by 15.5%. PACQLQ assessed mean overall score improved by 4.3% for the study period. Health care resources were compared for the study period and the corresponding period in the previous year. The resources associated with office visits and medications increased from retrospective to prospective. No ED visits were captured and laboratory tests were minimal.

      Conclusions

      The HEPAiRx® intervention demonstrated significant improvements in the HRQoL and PFT domains. The health care resources increased from the retrospective to prospective. Additional research is warranted.